Loading clinical trials...
Loading clinical trials...
Ofatumumab as Part of the Reduced Intensity Conditioning Regimen for Patients With High Risk Chronic Lymphocytic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation: a Pilot Study by GETH and GELLC
Conditions
Interventions
Ofatumumab
Locations
9
Spain
Hospital Germans Trias i Pujol
Badalona, Spain
Hospital de la Santa Creu Sant Pau
Barcelona, Spain
Hospital Vall d'Hebron
Barcelona, Spain
Institut Catala d'Oncologia
L'Hospitalet de Llobregat, Spain
Hospital La Princesa
Madrid, Spain
Hospital Puerta de Hierro
Madrid, Spain
Start Date
October 1, 2011
Primary Completion Date
October 1, 2014
Completion Date
October 1, 2017
Last Updated
May 6, 2022
NCT05006716
NCT07277231
NCT06859424
NCT05254743
NCT01804686
NCT05371808
Lead Sponsor
Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions